This educational program offers a comprehensive and clinically relevant exploration of the rapidly evolving endometrial cancer treatment landscape, with a particular focus understanding the dynamic and evolving competitive landscape. The curriculum is designed to address the need for deeper clarity around differences in trial design, key efficacy outcomes, and therapeutic positioning.

Through a detailed review of data from recent clinical trials and study designs, participants will gain critical insights into progression-free and overall survival (PFS/OS) subgroup analyses, including those based on MMR status, HRD, IO, P53 mutation profiles, and other biologically relevant subgroups. Special emphasis will be placed on interpreting unplanned analyses, understanding the impact of FDA approvals, and evaluating gaps in existing content that may hinder clinical decision-making. This program will incorporate emerging and established treatment options to help clinicians differentiate within a complex and competitive therapeutic landscape. Discussion will also highlight unmet needs, where treatment guidance remains less clear.

This fair and balanced program includes expert-led dialogue on how evolving data—both planned and exploratory—should be interpreted in practice and how these findings might reshape frontline and recurrent treatment strategies in endometrial cancer.